Charles Schwab Investment Management Inc. Grows Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

Charles Schwab Investment Management Inc. grew its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 35.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 102,854 shares of the company’s stock after purchasing an additional 26,964 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in scPharmaceuticals were worth $364,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Rice Hall James & Associates LLC increased its stake in scPharmaceuticals by 59.2% in the 4th quarter. Rice Hall James & Associates LLC now owns 989,635 shares of the company’s stock worth $3,503,000 after acquiring an additional 367,970 shares during the last quarter. Walleye Capital LLC grew its holdings in shares of scPharmaceuticals by 27.0% during the third quarter. Walleye Capital LLC now owns 475,555 shares of the company’s stock worth $2,169,000 after purchasing an additional 101,148 shares in the last quarter. Johnson Financial Group LLC purchased a new position in shares of scPharmaceuticals during the fourth quarter worth about $302,000. Geode Capital Management LLC increased its position in shares of scPharmaceuticals by 10.6% in the third quarter. Geode Capital Management LLC now owns 643,342 shares of the company’s stock worth $2,934,000 after purchasing an additional 61,582 shares during the last quarter. Finally, State Street Corp lifted its position in scPharmaceuticals by 5.2% during the third quarter. State Street Corp now owns 682,135 shares of the company’s stock valued at $3,111,000 after purchasing an additional 33,879 shares during the last quarter. Hedge funds and other institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Price Performance

SCPH opened at $2.33 on Wednesday. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The stock’s 50 day simple moving average is $3.22 and its 200 day simple moving average is $3.67. The firm has a market cap of $117.16 million, a price-to-earnings ratio of -1.23 and a beta of 0.40. scPharmaceuticals Inc. has a 1 year low of $2.31 and a 1 year high of $5.65.

scPharmaceuticals (NASDAQ:SCPH) last issued its earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. The firm had revenue of $12.15 million for the quarter, compared to analysts’ expectations of $12.08 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. As a group, analysts predict that scPharmaceuticals Inc. will post -1.53 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on SCPH shares. Maxim Group cut their target price on shares of scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a research note on Thursday, March 20th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.